Drugs that contain Istradefylline

1. Drug name - NOURIANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(1 year, 11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727994 KYOWA KIRIN Methods of treating patients suffering from movement disorders
Jan, 2023

(a month from now)

US7727993 KYOWA KIRIN Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy
Jan, 2023

(a month from now)

US8318201 KYOWA KIRIN Method of stabilizing diarylvinylene compound
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2024

Market Authorisation Date: 27 August, 2019

Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives said l-dopa therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in